Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00722228 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date changed from estimate of Jan 2021 to Mar 2025
    • Study completion date: Jan 2022 to Jan 2027
    v4
  2. Primary completion date: Jan 2019 to Jan 2021
    • Study completion date: Jan 2019 to Jan 2022
    v3
  3. Trial status: Not Yet Recruiting to Recruitingv2 Show 8 more changesShow less
    • Enrollment target: 50
    • Primary and study completion dates: Jan 2019
    • Start date: Jul 2008
    • Interventions: Allogeneic whole epithelial tumor cells, DNP-conjugated and irradiated (Biological) to Autologous or Allogeneic tumor cells (Biological)
    • Eligibility criteria expanded, about 11 words
    • Site details revised
    • Study arms: 0 to 1
    • Study title expanded, about 1 word
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Hadassah Medical Organization
47 trials monitored
See 2 trials at risk
Breast Cancer
5,418 trials monitored
See 296 trials at risk
Lung Cancer
4,790 trials monitored
See 263 trials at risk
Colorectal Cancer
3,394 trials monitored
See 159 trials at risk
and 4 more diseases
This study is based on the finding that tumor cells that are grown in the laboratory can be modified in such a way that, when injected to the patient, they will stimulate his/her immune response. This approach will be evaluated in patients with melanoma and colorectal, gastric, ovarian, breast, lung and kidney epithelial cancer. Tumor cells grown in the laboratory will be modified to make them stimulatory to the immune system, irradiated to kill them, and injected to the patient eight times at two-week intervals. This protocol is expected to prolong survival of metastatic cancer patients.
Trial Details
NCT Number NCT00722228
Lead Sponsor Hadassah Medical Organization
Conditions
(from sponsor)		 Colorectal Cancer, Ovarian Cancer, Gastric Cancer, Breast Cancer, Lung Cancer, Kidney Cancer, Melanoma
Related terms Breast Neoplasms, Colorectal Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Ovarian Neoplasms, Stomach Neoplasms
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov